Japan Might Revise Apology on Wartime Sex Slaves

TOKYO — A top official hinted on Thursday that Japan’s newly installed conservative government might seek to revise a two-decade-old official apology to women forced into sexual slavery during World War II, a move that would most likely outrage South Korea and possibly other former victims of Japanese militarism.

Speaking a day after the new cabinet was named, Chief Cabinet Secretary Yoshihide Suga, who serves as the government’s top spokesman, refused to say clearly whether the new prime minister, Shinzo Abe, would uphold the 1993 apology, which was issued by the chief cabinet secretary at the time, Yohei Kono.

Mr. Suga said at a news conference, however, that it would be “desirable for experts and historians to study” the statement, which acknowledged the Imperial Army’s involvement in forcing thousands of Asian and Dutch women to provide sex for Japanese soldiers.

Mr. Suga seemed to keep his comments intentionally vague, adding only that the matter “should not be made into a political or diplomatic issue.” He also said the Abe government would uphold a broader apology, issued in 1995 to observe the 50th anniversary of the end of World War II, to all victims of Japan’s colonialism and aggression.

The sex slaves issue remains highly emotional in South Korea, a former Japanese colony. On Thursday, the South Korean Foreign Ministry responded to Mr. Suga’s comments by calling on Japan not to forget its militaristic past.

The Kono Statement has long been a sore point for Japanese rightists, who deny either that the women had been coerced or that the military had a hand in forcing them to become what many Japanese euphemistically call “comfort women.” These critics include Mr. Abe, an outspoken nationalist who has repeatedly called for revising the statement, most recently during an internal Liberal Democratic Party election in September.

The issue does not resonate broadly, however, among the general public, which would rather avoid confrontation with other Asian countries. During the national parliamentary elections this month that swept his Liberal Democrats back into power, Mr. Abe avoided talking about the matter, apparently so as not to be seen as too far to the right of mainstream voters.

His position has also caused concern in Washington, where the United States government has urged Japan and South Korea, its two closest Asian allies, to increase cooperation against security threats like North Korea.

In the summer, the South Korean president at the time, Lee Myung-bak, visited a group of islands claimed by both his nation and Japan in an apparent display of displeasure over Japan’s refusal to pay official compensation to South Korea’s few hundred surviving former sex slaves, now in their 80s.

South Korea’s newly elected president, Park Geun-hye, has also shown interest, attending United States Congressional hearings in 2007 on the issue.

Read More..

Chicken Farms Try Oregano as Antibiotic Substitute

Jessica Kourkounis for The New York Times

Chickens raised for Bell & Evans, like these in Pennsylvania, eat feed laced with oregano oil.

FREDERICKSBURG, Pa. — The smell of oregano wafting from Scott Sechler’s office is so strong that anyone visiting Bell & Evans these days could be forgiven for wondering whether Mr. Sechler has forsaken the production of chicken and gone into pizza.

Oregano lies loose in trays and tied into bunches on tabletops and counters, and a big, blue drum that held oregano oil stands in the corner. “Have you ever tried oregano tea?” Mr. Sechler asked, mashing leaves between his broad fingers.

Off and on over the last three years or so, his chickens have been eating a specially milled diet laced with oregano oil and a touch of cinnamon. Mr. Sechler swears by the concoction as a way to fight off bacterial diseases that plague meat and poultry producers without resorting to antibiotics, which some experts say can be detrimental to the humans who eat the meat. Products at Bell & Evans, based in this town about 30 miles east of Harrisburg, have long been free of antibiotics, contributing to the company’s financial success as consumers have demanded purer foods.

But Mr. Sechler said that nothing he had used as a substitute in the past worked as well as oregano oil.

“I have worried a bit about how I’m going to sound talking about this,” he said. “But I really do think we’re on to something here.”

Skeptics of herbal medicines abound, as any quick Internet search demonstrates. “Oil of oregano is a perennial one, advertised as a cure for just about everything,” said Scott Gavura, a pharmacist in Toronto who writes for the Web site Science-Based Medicine. “But there isn’t any evidence, there are too many unanswered questions and the only proponents for it are the ones producing it.”

Nonetheless, Mr. Gavura said he would welcome a reduction in the use of antibiotics in animals.

At the same time, consumers are growing increasingly sophisticated about the content of the foods that they eat.

Data on sales of antibiotic-free meat is hard to come by, but the sales are a tiny fraction of the overall meat market. Sales in the United States of organic meat, poultry and fish, which by law must be raised without antibiotics, totaled $538 million in 2011, according to the Organic Trade Association. By comparison, sales of all beef that year were $79 billion.

Still, retailers like Costco, Whole Foods and Trader Joe’s, as well as some restaurant chains, complain that they cannot get enough antibiotic-free meat.

Noodles & Company, a fast-growing chain of more than 300 restaurants, recently added antibiotic-free pork to the choices of ingredients that customers can add to their made-to-order pastas. It ensured its supply by ordering cuts of meat that were not in relatively high demand and by committing in advance to buy a year’s worth, said Dan Fogarty, its executive vice president for marketing.

“We’re deliberately voting with our pocketbooks,” he said.

In a nationwide telephone survey of 1,000 adults in March, more than 60 percent told the Consumer Reports National Research Center that they would be willing to pay at least 5 cents a pound more for meat raised without antibiotics.

“Before, it was kind of a nice little business, and while it’s still microscopic in the grand scheme of things, we’re seeing acceptance from retailers across the country, not just in California and on the East Coast,” said Stephen McDonnell, founder and chief executive of Applegate, an organic and natural meats company.

Mr. McDonnell said a confluence of trends, from heightened interest in whole and natural foods to growing concerns about medical problems like diabetes, obesity and gluten allergies, were contributing to the demand for antibiotic-free meat.

There is growing concern among health care experts and policy makers about antibiotic resistance and the rise of “superbugs,” bacteria that are impervious to one or more antibiotics. Those bacteria can be passed on to consumers, who eat meat infected with them and then cannot be treated.

In November, the Centers for Disease Control and Prevention and 25 national health organizations and advocacy groups issued a statement on antibiotics that, among other things, called for “limiting the use of medically important human antibiotics in food animals” and “supporting the use of such antibiotics in animals only for those uses that are considered necessary for assuring animal health.”

In 2011, there were several prominent recalls involving bacterial strains that are resistant to antibiotics, including more than 60 million pounds of ground beef contaminated with salmonella Typhimurium and about 36 million pounds of ground turkey spoiled with salmonella Heidelberg.

Consumer Reports released a study last month that found the bacteria Yersinia enterocolitica in 69 percent of 198 pork chop and ground pork samples bought at stores around the country. Some of the bacteria were resistant to one or more antibiotics.

Analysis of Food and Drug Administration data by the Center for Science in the Public Interest found that 80 percent of all antibiotics sold in the United States are used in animals. The majority of those antibiotics are used to spur growth or prevent infections from spreading in the crowded conditions in which most animal production takes place today.

The European Union has banned the use of antibiotics to accelerate growth, and the European Parliament is pushing to end their use as tools to prevent disease as well.

The oregano oil product Mr. Sechler uses, By-O-Reg Plus, is made by a Dutch company, Ropapharm International. In the late 1990s, Bayer conducted trials on the product, known as Ropadiar in Europe, comparing its ability to control diarrhea in piglets caused by E. coli with that of four of the company’s products.

Read More..

Chicken Farms Try Oregano as Antibiotic Substitute

Jessica Kourkounis for The New York Times

Chickens raised for Bell & Evans, like these in Pennsylvania, eat feed laced with oregano oil.

FREDERICKSBURG, Pa. — The smell of oregano wafting from Scott Sechler’s office is so strong that anyone visiting Bell & Evans these days could be forgiven for wondering whether Mr. Sechler has forsaken the production of chicken and gone into pizza.

Oregano lies loose in trays and tied into bunches on tabletops and counters, and a big, blue drum that held oregano oil stands in the corner. “Have you ever tried oregano tea?” Mr. Sechler asked, mashing leaves between his broad fingers.

Off and on over the last three years or so, his chickens have been eating a specially milled diet laced with oregano oil and a touch of cinnamon. Mr. Sechler swears by the concoction as a way to fight off bacterial diseases that plague meat and poultry producers without resorting to antibiotics, which some experts say can be detrimental to the humans who eat the meat. Products at Bell & Evans, based in this town about 30 miles east of Harrisburg, have long been free of antibiotics, contributing to the company’s financial success as consumers have demanded purer foods.

But Mr. Sechler said that nothing he had used as a substitute in the past worked as well as oregano oil.

“I have worried a bit about how I’m going to sound talking about this,” he said. “But I really do think we’re on to something here.”

Skeptics of herbal medicines abound, as any quick Internet search demonstrates. “Oil of oregano is a perennial one, advertised as a cure for just about everything,” said Scott Gavura, a pharmacist in Toronto who writes for the Web site Science-Based Medicine. “But there isn’t any evidence, there are too many unanswered questions and the only proponents for it are the ones producing it.”

Nonetheless, Mr. Gavura said he would welcome a reduction in the use of antibiotics in animals.

At the same time, consumers are growing increasingly sophisticated about the content of the foods that they eat.

Data on sales of antibiotic-free meat is hard to come by, but the sales are a tiny fraction of the overall meat market. Sales in the United States of organic meat, poultry and fish, which by law must be raised without antibiotics, totaled $538 million in 2011, according to the Organic Trade Association. By comparison, sales of all beef that year were $79 billion.

Still, retailers like Costco, Whole Foods and Trader Joe’s, as well as some restaurant chains, complain that they cannot get enough antibiotic-free meat.

Noodles & Company, a fast-growing chain of more than 300 restaurants, recently added antibiotic-free pork to the choices of ingredients that customers can add to their made-to-order pastas. It ensured its supply by ordering cuts of meat that were not in relatively high demand and by committing in advance to buy a year’s worth, said Dan Fogarty, its executive vice president for marketing.

“We’re deliberately voting with our pocketbooks,” he said.

In a nationwide telephone survey of 1,000 adults in March, more than 60 percent told the Consumer Reports National Research Center that they would be willing to pay at least 5 cents a pound more for meat raised without antibiotics.

“Before, it was kind of a nice little business, and while it’s still microscopic in the grand scheme of things, we’re seeing acceptance from retailers across the country, not just in California and on the East Coast,” said Stephen McDonnell, founder and chief executive of Applegate, an organic and natural meats company.

Mr. McDonnell said a confluence of trends, from heightened interest in whole and natural foods to growing concerns about medical problems like diabetes, obesity and gluten allergies, were contributing to the demand for antibiotic-free meat.

There is growing concern among health care experts and policy makers about antibiotic resistance and the rise of “superbugs,” bacteria that are impervious to one or more antibiotics. Those bacteria can be passed on to consumers, who eat meat infected with them and then cannot be treated.

In November, the Centers for Disease Control and Prevention and 25 national health organizations and advocacy groups issued a statement on antibiotics that, among other things, called for “limiting the use of medically important human antibiotics in food animals” and “supporting the use of such antibiotics in animals only for those uses that are considered necessary for assuring animal health.”

In 2011, there were several prominent recalls involving bacterial strains that are resistant to antibiotics, including more than 60 million pounds of ground beef contaminated with salmonella Typhimurium and about 36 million pounds of ground turkey spoiled with salmonella Heidelberg.

Consumer Reports released a study last month that found the bacteria Yersinia enterocolitica in 69 percent of 198 pork chop and ground pork samples bought at stores around the country. Some of the bacteria were resistant to one or more antibiotics.

Analysis of Food and Drug Administration data by the Center for Science in the Public Interest found that 80 percent of all antibiotics sold in the United States are used in animals. The majority of those antibiotics are used to spur growth or prevent infections from spreading in the crowded conditions in which most animal production takes place today.

The European Union has banned the use of antibiotics to accelerate growth, and the European Parliament is pushing to end their use as tools to prevent disease as well.

The oregano oil product Mr. Sechler uses, By-O-Reg Plus, is made by a Dutch company, Ropapharm International. In the late 1990s, Bayer conducted trials on the product, known as Ropadiar in Europe, comparing its ability to control diarrhea in piglets caused by E. coli with that of four of the company’s products.

Read More..

Netflix Fixes a Disruption to Its Video Streaming

A disruption at one of Amazon’s Web service centers hit users of Netflix’s streaming video service on Christmas Eve and was not fully resolved until Christmas Day, a Netflix spokesman said on Tuesday.

The disruption affected Netflix subscribers across the United States, Canada and Latin America and blacked out various devices — including video game consoles and DVD players — that enable users to stream movies and television shows, the Netflix spokesman, Joris Evers, said.

Mr. Evers said the issue was the result of a failure at an Amazon Web Services cloud computing center in Virginia and started at about 3:30 p.m. Eastern time on Monday and was fully restored Tuesday morning, although streaming was available for most users late on Monday.

“We are investigating exactly what happened and how it could have been prevented,” Mr. Evers said.

“We are happy that people opening gifts of Netflix or Netflix-capable devices can watch TV shows and movies and apologize for any inconvenience caused last night,” he added.

A disruption at Amazon Web Services knocked out sites like Flipboard and Foursquare in October, and a storm in June similarly affected services like Netflix, Instagram and Pinterest.

Read More..

Russian Parliament Sends Adoption Ban to Putin

MOSCOW — The upper chamber of Parliament on Wednesday unanimously approved a bill to ban adoptions of Russian children by United States citizens, sending the measure to President Vladimir V. Putin, who has voiced support but not yet said if he will sign it.

Enactment of the adoption ban, which was developed in retaliation for an American law punishing Russians accused of violating human rights, would be the most severe blow yet to relations between Russia and the United States in a year marked by a series of setbacks.

Since Mr. Putin returned to the presidency in May, Russian officials have used a juggernaut of legislation and executive decisions to curtail United States influence and involvement in Russia, undoing major partnerships that began after the fall of the Soviet Union.

In September, the Kremlin ordered the United States Agency for International Development to cease operations here, shutting a wide portfolio of public health, civil society and other initiatives. And officials announced plans to terminate a joint effort to dismantle nuclear, chemical and other nonconventional weapons known as the Nunn-Lugar agreement.

Russia also passed a law requiring nonprofit groups that get financing from abroad to register as “foreign agents,” sharply curtailing the ability of the United States to work with good-government groups, and another law broadening the definition of treason to include “providing financial, technical, advisory or other assistance to a foreign state or international organization.”

The adoption ban, however, is the first step that takes direct aim at the American public and would effectively undo a bilateral agreement on international adoptions that took effect on Nov. 1. The agreement called for heightened oversight in response to several high-profile cases of abuse and deaths of adopted Russian children in the United States.

About 1,000 Russian children were adopted by parents from the United States in 2011, more than any other country, and more than 45,000 such children have been adopted by American parents since 1999.

Pavel Astakhov, Russia’s child rights commissioner, told news agencies on Wednesday that the ban, if enacted, could prevent the departure of 46 children who are ready to be adopted by parents from the United States. Some of those adoptions have already received court approval, he said. And some lawmakers said they believed that the bilateral agreement on adoptions with the United States would be void as of Jan. 1, even though Mr. Putin, at his annual news conference last week, said that changes to the agreement required one-year notice by either side.

The proposed ban has opened a rare split at the highest levels of the Russian government, with several senior officials speaking out against it. And it has provoked a huge public outcry and debate, with critics of the ban saying that it would most hurt Russian orphans, many of whom are already suffering in the country’s deeply troubled foster care and orphanage system.

In debate on Wednesday, lawmakers said that they felt an imperative to retaliate for a law signed by President Obama this month that will punish Russian citizens accused of violating human rights, by prohibiting them from traveling to the United States and from owning real estate or other assets there.

Lawmakers also said that Russia, which has more than 650,000 children living without parental supervision, should take care of them on its own. The vote in the Federation Council was 143 to 0.

“We need to set a plan for the future,” said Valery V. Ryazanksy, a senator from the Kursk region. Then, reiterating a slogan adopted by many lawmakers in recent days, he declared: “Russia without orphans!” Gennady I. Makin, a senator from Veronezh, gave it a slight twist: “Russia without orphanages.”

Several child-welfare advocates have mocked this sort of talk, noting that more than 80,000 children were identified as in need of supervision in 2011 and that the country had been unable to find homes for a vast majority of children eligible for adoption.

There were slightly more than 10,000 adoptions in Russia in 2011, about 3,400 of which were by foreigners.

In addition to banning adoptions by Americans, the bill approved on Wednesday would impose sanctions on American judges and others accused of violating the rights of adopted Russian children in the United States.

A number of cases involving the abuse or even the deaths of adopted Russian children in recent years have generated publicity and outrage in Russia, including a case in which a 7-year-old boy was sent on a flight back to Russia alone by his adoptive mother in Tennessee.

The Russian law was named for Dmitri Yakovlev, a toddler who died of heatstroke in Virginia in 2008, after his adoptive father left him in a parked car for nine hours. The father, Miles Harrison, was acquitted of manslaughter by a judge who ruled that the death was an accident.

Read More..

Israel to Review Curbs on Women’s Prayer at Western Wall

JERUSALEM – Amid outrage across the Jewish diaspora over a flurry of recent arrests of women seeking to pray at the Western Wall with ritual garments – in defiance of Israeli law — Prime Minister Benjamin Netanyahu has asked Natan Sharansky, the chairman of the Jewish Agency, to study the issue and suggest ways to make the site more accommodating to all Jews.

The move comes after more than two decades of civil disobedience by a group called Women of the Wall against regulations, legislation and a 2003 Supreme Court ruling that allow for gender division at the wall, one of Judaism’s holiest sites, and prohibit women from carrying a Torah or wearing prayer shawls there.

Though the movement has struggled to gain traction here in Israel, where the ultra-Orthodox retain great sway over public life, the issue has deepened a divide between the Jewish state and the Jewish diaspora at a time when Israel is battling international isolation over its settlement policy. Critics, particularly leaders of the Reform and Conservative movements in the United States, complain that the government’s recent aggressive enforcement of restrictions at the wall has turned a national monument into an ultra-Orthodox synagogue.

“The prime minister thinks the Western Wall has to be a site that expresses the unity of the Jewish people, both inside Israel and outside the state of Israel,” Ron Dermer, Mr. Netanyahu’s senior adviser, said in an interview Tuesday. “He wants to preserve the unity of world Jewry. This is an important component of Israel’s strength.”

Mr. Sharansky, whose quasi-governmental nonprofit organization handles immigration for the state and is a bridge between Israel and Jews around the world, said that Mr. Netanyahu had asked him on Monday to take up the matter, and that he expected to have recommendations within “a few months.” He and Mr. Dermer said the agenda would include improvements for Robinson’s Arch, a discreet area of the wall designated for coed prayer under the court ruling, and easing of restrictions in the larger area known as the Western Wall plaza, along with the more sensitive questions regarding prayer at the main site.

The Jewish Agency itself stopped having ceremonies for new immigrants in the plaza about two years ago after the Western Wall Heritage Foundation, which controls the site, said that men and women could not sit together. Under pressure from the international groups that provide its financing, the agency on Oct. 30 passed a resolution calling for a “satisfactory approach to the issue of prayer at the Western Wall.”

Asked whether he could imagine a day when women could wear prayer shawls and read Torah at the wall itself, Mr. Sharansky said, “I imagine very easily a situation where everybody will have their opportunity to express their solidarity with Judaism and the Jewish people and the state of Israel in a way he or she wants, without undermining the other.”

“That’s as much as I want to say at this moment,” he added. “Now I have to share this vision with the appropriate bodies.”

Anat Hoffman, chairwoman of Women of the Wall, reacted with cautious optimism to Mr. Netanyahu’s initiative, but said it would not stop the Israel Religious Action Center, of which she is executive director, from filing a Supreme Court petition as soon as next week challenging the ultra-Orthodox majority on the heritage foundation’s board.

“It’s a good thing that after 24 years the highest echelons in Israel are actually paying attention to this rift that is breaking diaspora Jews from Israel,” she said. “The table that should run the Western Wall should have everyone who has an interest in the wall sitting around it.”

Ms. Hoffman said the women’s group would be satisfied if it was allowed to pray at the wall once a month with full regalia, but that the religious action center would like hours each day, between scheduled prayer times, where the gender partition is removed and people can freely enjoy the site as a cultural monument.

“If in the end what happens is that the Robinson’s Arch area will be run by the Jewish Agency instead of the antiquities department, then we’re talking about who’s going to take care of the air conditioning in the back of the bus,” she said. “I don’t care about that. I don’t want to sit in the back of the bus. I want to dismantle the Western Wall Heritage Foundation.”

Abraham H. Foxman, director of the Anti-Defamation League, said he had discussed the wall and other questions of religious pluralism with Mr. Netanyahu in Jerusalem on Monday.

“This is a wise initiative, but it’s only a beginning,” Mr. Foxman said.

Read More..

Gadgetwise Blog: A Gaming Laptop That's Quick and Costly

The word “extreme” may be overused in describing male-dominated activities like the X Games or the cinnamon challenge, but it fits the bill when it comes to the Razer Blade gaming laptop.

It is extremely fast, extremely thin and extremely expensive.

I don’t play computer games so I turned the Razer Blade over to two lifelong gamers, Evan and Morgan Dilks. Evan, as the owner of the Firehouse Coffee Company in Baltimore, has spent plenty of caffeinated play time on game consoles, like the PlayStation 3 and Xbox 360 he currently owns.

The pair tried out Battlefield 3, which came preinstalled for demonstration on the machine. “One of the pros was how fast it was,” said Evan. “The processor is just crazy.” That crazy processor is an Intel Core i7, a quad-core chip found in some high end Macs.

That speed is paired with a 17.3-inch high-definition screen impressive enough that the brothers spent some time watching videos on it. Although the laptop is almost 11-by-17-inches to accommodate the screen, it is less than an inch thick and weighs 6.6 pounds, relatively light for a laptop this size. Part of the way Razer kept it thin was by omitting an optical drive.

What really sets it apart from other laptops is the Switchblade user interface. That is an LCD trackpad that shows game information, like who in your player group is inflicting the most damage on foes. Evan said his brother Morgan adjusted more easily to the controls than he did, but he caught on eventually.

There are also 10 buttons above the trackpad that change their assigned functions depending on the game. They can represent different weapons, and automate actions that would normally take several steps, like drawing and loading a firearm. Or you can create your own custom actions, even for non-gaming software, like if you wanted to use the laptop for Photoshop.

What the brothers did not like about the Razer Blade was the price: $2,500. “That is a huge investment,” said Evan. “Add in accessories like a sound system, headset, game and gaming subscription, and special controllers you might need, and the price keeps rising.”

Read More..

Madrid Journal: Spain Turns Christmas Into a Season of Thrift

MADRID — This is the season when barren stone plazas and broad sidewalks here fill with Christmas markets peddling sweets, candles, holiday decorations and crafts. But alongside the festive stalls this year, another kind of market has sprung up in response to Spain’s hard times.

They are the “mercadillos,” or little markets, where the entrepreneurial-minded have found a niche by gathering and selling the unsold stock of more established retailers whose sales have plummeted, or unwanted clothing and other items from people in need of cash.

Buyers and sellers rely heavily on Facebook and other social networking sites to promote the improvised exchanges, which have transformed the way Spaniards shop for the holidays.

For the hard-pressed, the markets are a bargain hunters’ paradise, and for the jobless, they offer an economic lifeline and a chance to recast their fortunes.

Cristina Aresti and Sofía Bourne had never thought about working in fashion until they lost their jobs, joining the more than 25 percent of Spaniards who are unemployed. But this month they opened Abo Cool Market, a pop-up shop that sold secondhand women’s clothing over six days inside a Madrid furniture store.

The two women said they had intended to limit their sales to 500 items. But given the avalanche of offers from people wanting to sell off their wardrobes, they ended up selecting 800 pieces of clothing, with a combined retail value of more than $59,000.

“We just couldn’t believe how many people now want to sell clothing that they had hardly worn,” Ms. Bourne said. Among the most expensive items on sale — a totem of more prosperous times — was an unworn Gucci silk dress that still bore its original sales tag. It was on sale for $650, about a quarter of the original price.

Ms. Aresti and Ms. Bourne will keep 35 percent of their sales receipts; the rest will go to the women who supplied the clothing. The original owners then have the choice of either retrieving unsold items or donating them to charity groups.

Many of the people running this year’s mercadillos had little or no experience in retail sales. Ms. Bourne was laid off by a real estate company; Ms. Aresti lost her job as director of a company that organizes business conferences.

“I don’t yet know whether my future really lies in fashion,” Ms. Aresti said, “but there comes a point in such a hopeless job market when you’ve at least got to try to reinvent yourself.”

Even merchants with long experience in retail or fashion are borrowing some of the practices of the little markets as a way to lure customers.

“Store sales have been plummeting, so you need to go out of your way to make it fun and worthwhile for people to still do some shopping this Christmas,” said Cristina Terrón, a fashion stylist whose mercadillo sold some clothing she had initially selected for television and movie productions. “Something that started out of economic necessity is now also turning into a fashion.”

On average, Spanish households are set to spend $790 to $920 on Christmas shopping this year, down as much as 38 percent from 2007, before the onset of the economic crisis, according to a study published this month by Esade, a Spanish business school.

Jaime Castelló, a marketing professor and one of the authors of the study, said the crisis was not only reducing spending, but also speeding up changes in consumer habits.

About 70 percent of Spanish households said they would search online before buying any Christmas gifts, and 25 percent said they would not even step into a department store, according to the study. The mercadillos, Mr. Castelló suggested, were “another alternative in this crisis to the traditional buying channels.”

Ana María Menoyo Delgado, 26, said she had “lots of fun” searching the Christmas mercadillo Web sites as she worked her way through her holiday shopping list. At Abo Cool’s market, with her mother’s help, she ended up with two designer hand bags, a skirt and a coat, spending a total of $659.

While bargain hunting is part of the attraction, several buyers said they simply preferred the mercadillos to department stores.

“I can’t stand anymore walking into a conventional luxury store where you are likely to be welcomed by a pretty and young but utterly grumpy sales attendant,” Irene Trigueros, a commodities trader, said as she tried on a pair of secondhand sunglasses.

Some of the mercadillos have even been held in bars. “Having a cocktail while trying on some nice clothing seems to me a perfect way to end the day,” said Alberto Martínez, owner of the 1862 Dry Bar, who allowed his basement to become a mercadillo for three days this month.

Mr. Martínez did not charge any rent, but some of the larger mercadillos add to their revenue by renting out booths in their spaces to smaller sellers, normally for $200 to $400 a weekend.

In Alcobendas, on the outskirts of Madrid, a warehouse was transformed into La Galería del 32, a market that sold, among other things, wine, ham, sculpture, jewelry and handbags. The warehouse used to store electronics equipment and other goods until about three years ago, when the demand for storage space dried up as retail sales slumped.

“This kind of event is a great way for those who exhibit to attract more shoppers, while we earn something from renting the space rather than allowing it to stand empty,” said Leticia Martínez Rubio, one of the organizers.

A charity foundation, the Fundacíon Dar, also took part in the weekend event, encouraging shoppers to bring toys that the foundation would distribute to underprivileged children in the Madrid area.

“Beside having a successful weekend sale, I think it’s also important to keep some of the Christmas spirit,” Ms. Martínez Rubio said.

Read More..

Genetic Gamble : Drugs Aim to Make Several Types of Cancer Self-Destruct

C.J. Gunther for The New York Times

Dr. Donald Bergstrom is a cancer specialist at Sanofi, one of three companies working on a drug to restore a tendency of damaged cells to self-destruct.

For the first time ever, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of cancers independently of where they originated — breast, prostate, liver, lung. The drugs go after an aberration involving a cancer gene fundamental to tumor growth. Many scientists see this as the beginning of a new genetic age in cancer research.

Great uncertainties remain, but such drugs could mean new treatments for rare, neglected cancers, as well as common ones. Merck, Roche and Sanofi are racing to develop their own versions of a drug they hope will restore a mechanism that normally makes badly damaged cells self-destruct and could potentially be used against half of all cancers.

No pharmaceutical company has ever conducted a major clinical trial of a drug in patients who have many different kinds of cancer, researchers and federal regulators say. “This is a taste of the future in cancer drug development,” said Dr. Otis Webb Brawley, the chief medical and scientific officer of the American Cancer Society. “I expect the organ from which the cancer came from will be less important in the future and the molecular target more important,” he added.

And this has major implications for cancer philanthropy, experts say. Advocacy groups should shift from fund-raising for particular cancers to pushing for research aimed at many kinds of cancer at once, Dr. Brawley said. John Walter, the chief executive officer of the Leukemia and Lymphoma Society, concurred, saying that by pooling forces “our strength can be leveraged.”

At the heart of this search for new cancer drugs are patients like Joe Bellino, who was a post office clerk until his cancer made him too sick to work. Seven years ago, he went into the hospital for hernia surgery, only to learn he had liposarcoma, a rare cancer of fat cells. A large tumor was wrapped around a cord that connects the testicle to the abdomen. “I was shocked,” he said in an interview this summer.

Companies have long ignored liposarcoma, seeing no market for drugs to treat a cancer that strikes so few. But it is ideal for testing Sanofi’s drug because the tumors nearly always have the exact genetic problem the drug was meant to attack — a fusion of two large proteins. If the drug works, it should bring these raging cancers to a halt. Then Sanofi would test the drug on a broad range of cancers with a similar genetic alteration. But if the drug fails against liposarcoma, Sanofi will reluctantly admit defeat.

“For us, this is a go/no-go situation,” said Laurent Debussche, a Sanofi scientist who leads the company’s research on the drug.

The genetic alteration the drug targets has tantalized researchers for decades. Normal healthy cells have a mechanism that tells them to die if their DNA is too badly damaged to repair. Cancer cells have grotesquely damaged DNA, so ordinarily they would self-destruct. A protein known as p53 that Dr. Gary Gilliland of Merck calls the cell’s angel of death normally sets things in motion. But cancer cells disable p53, either directly, with a mutation, or indirectly, by attaching the p53 protein to another cellular protein that blocks it. The dream of cancer researchers has long been to reanimate p53 in cancer cells so they will die on their own.

The p53 story began in earnest about 20 years ago. Excitement ran so high that, in 1993, Science magazine anointed it Molecule of the Year and put it on the cover. An editorial held out the possibility of “a cure of a terrible killer in the not too distant future.”

Companies began chasing a drug to restore p53 in cells where it was disabled by mutations. But while scientists know how to block genes, they have not figured out how to add or restore them. Researchers tried gene therapy, adding good copies of the p53 gene to cancer cells. That did not work.

Then, instead of going after mutated p53 genes, they went after half of cancers that used the alternative route to disable p53, blocking it by attaching it to a protein known as MDM2. When the two proteins stick together, the p53 protein no longer functions. Maybe, researchers thought, they could find a molecule to wedge itself between the two proteins and pry them apart.

The problem was that both proteins are huge and cling tightly to each other. Drug molecules are typically tiny. How could they find one that could separate these two bruisers, like a referee at a boxing match?

In 1996, researchers at Roche noticed a small pocket between the behemoths where a tiny molecule might slip in and pry them apart. It took six years, but Roche found such a molecule and named it Nutlin because the lab was in Nutley, N.J.

But Nutlins did not work as drugs because they were not absorbed into the body.

Roche, Merck and Sanofi persevered, testing thousands of molecules.

At Sanofi, the stubborn scientist leading the way, Dr. Debussche, maintained an obsession with p53 for two decades. Finally, in 2009, his team, together with Shaomeng Wang at the University of Michigan and a biotech company, Ascenta Therapeutics, found a promising compound.

The company tested the drug by pumping it each day into the stomachs of mice with sarcoma.

Read More..

Genetic Gamble : Drugs Aim to Make Several Types of Cancer Self-Destruct

C.J. Gunther for The New York Times

Dr. Donald Bergstrom is a cancer specialist at Sanofi, one of three companies working on a drug to restore a tendency of damaged cells to self-destruct.

For the first time ever, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of cancers independently of where they originated — breast, prostate, liver, lung. The drugs go after an aberration involving a cancer gene fundamental to tumor growth. Many scientists see this as the beginning of a new genetic age in cancer research.

Great uncertainties remain, but such drugs could mean new treatments for rare, neglected cancers, as well as common ones. Merck, Roche and Sanofi are racing to develop their own versions of a drug they hope will restore a mechanism that normally makes badly damaged cells self-destruct and could potentially be used against half of all cancers.

No pharmaceutical company has ever conducted a major clinical trial of a drug in patients who have many different kinds of cancer, researchers and federal regulators say. “This is a taste of the future in cancer drug development,” said Dr. Otis Webb Brawley, the chief medical and scientific officer of the American Cancer Society. “I expect the organ from which the cancer came from will be less important in the future and the molecular target more important,” he added.

And this has major implications for cancer philanthropy, experts say. Advocacy groups should shift from fund-raising for particular cancers to pushing for research aimed at many kinds of cancer at once, Dr. Brawley said. John Walter, the chief executive officer of the Leukemia and Lymphoma Society, concurred, saying that by pooling forces “our strength can be leveraged.”

At the heart of this search for new cancer drugs are patients like Joe Bellino, who was a post office clerk until his cancer made him too sick to work. Seven years ago, he went into the hospital for hernia surgery, only to learn he had liposarcoma, a rare cancer of fat cells. A large tumor was wrapped around a cord that connects the testicle to the abdomen. “I was shocked,” he said in an interview this summer.

Companies have long ignored liposarcoma, seeing no market for drugs to treat a cancer that strikes so few. But it is ideal for testing Sanofi’s drug because the tumors nearly always have the exact genetic problem the drug was meant to attack — a fusion of two large proteins. If the drug works, it should bring these raging cancers to a halt. Then Sanofi would test the drug on a broad range of cancers with a similar genetic alteration. But if the drug fails against liposarcoma, Sanofi will reluctantly admit defeat.

“For us, this is a go/no-go situation,” said Laurent Debussche, a Sanofi scientist who leads the company’s research on the drug.

The genetic alteration the drug targets has tantalized researchers for decades. Normal healthy cells have a mechanism that tells them to die if their DNA is too badly damaged to repair. Cancer cells have grotesquely damaged DNA, so ordinarily they would self-destruct. A protein known as p53 that Dr. Gary Gilliland of Merck calls the cell’s angel of death normally sets things in motion. But cancer cells disable p53, either directly, with a mutation, or indirectly, by attaching the p53 protein to another cellular protein that blocks it. The dream of cancer researchers has long been to reanimate p53 in cancer cells so they will die on their own.

The p53 story began in earnest about 20 years ago. Excitement ran so high that, in 1993, Science magazine anointed it Molecule of the Year and put it on the cover. An editorial held out the possibility of “a cure of a terrible killer in the not too distant future.”

Companies began chasing a drug to restore p53 in cells where it was disabled by mutations. But while scientists know how to block genes, they have not figured out how to add or restore them. Researchers tried gene therapy, adding good copies of the p53 gene to cancer cells. That did not work.

Then, instead of going after mutated p53 genes, they went after half of cancers that used the alternative route to disable p53, blocking it by attaching it to a protein known as MDM2. When the two proteins stick together, the p53 protein no longer functions. Maybe, researchers thought, they could find a molecule to wedge itself between the two proteins and pry them apart.

The problem was that both proteins are huge and cling tightly to each other. Drug molecules are typically tiny. How could they find one that could separate these two bruisers, like a referee at a boxing match?

In 1996, researchers at Roche noticed a small pocket between the behemoths where a tiny molecule might slip in and pry them apart. It took six years, but Roche found such a molecule and named it Nutlin because the lab was in Nutley, N.J.

But Nutlins did not work as drugs because they were not absorbed into the body.

Roche, Merck and Sanofi persevered, testing thousands of molecules.

At Sanofi, the stubborn scientist leading the way, Dr. Debussche, maintained an obsession with p53 for two decades. Finally, in 2009, his team, together with Shaomeng Wang at the University of Michigan and a biotech company, Ascenta Therapeutics, found a promising compound.

The company tested the drug by pumping it each day into the stomachs of mice with sarcoma.

Read More..